On this page
What each program costs in Indiana
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $41/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $69/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 10 | Semaglutide | month to month | $129/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 13 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 14 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 15 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 16 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 17 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 18 | Slim (Compounded Oral Semaglutide) | month to month | $299/mo | none | too few reviews | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the State of Indiana employee health plan cover GLP-1s for weight loss?
Indiana's state employee pharmacy benefit stopped covering GLP-1 drugs used for weight loss on January 1, 2026.
Does Indiana Medicaid cover GLP-1s for weight loss?
Not covered for weight loss
Indiana Medicaid's criteria dated July 1, 2026 say Wegovy and Zepbound are not covered exclusively for weight loss; updated GLP-1 criteria apply to requests from January 1, 2027, and we could not read them. Read from state documents Nov 6, 2026.
What Indiana Medicaid's documents say about each drug for weight loss. Read Nov 6, 2026. Indiana Family and Social Services Administration, with Optum Rx as pharmacy vendor.
WegovyNo
Not covered exclusively for weight loss. The criteria have prior authorization paths for heart disease risk reduction and for MASH.
“WEGOVY (SEMAGLUTIDE) INJECTION FORMULATION (NOT COVERED EXCLUSIVELY FOR WEIGHT LOSS)”
Criteria for Indiana Medicaid, prepared for the State of Indiana by OptumRx · Effective Jul 1, 2026 · read Nov 6, 2026
“WEGOVY (SEMAGLUTIDE) ORAL FORMULATION (NOT COVERED EXCLUSIVELY FOR WEIGHT LOSS”
Criteria for Indiana Medicaid, prepared for the State of Indiana by OptumRx · Effective Jul 1, 2026 · read Nov 6, 2026
ZepboundNo
Not covered exclusively for weight loss. The criteria have a prior authorization path for adults with moderate to severe sleep apnea and BMI of 30 or higher.
“ZEPBOUND (TIRZEPATIDE) (NOT COVERED EXCLUSIVELY FOR WEIGHT LOSS)”
Criteria for Indiana Medicaid, prepared for the State of Indiana by OptumRx · Effective Jul 1, 2026 · read Nov 6, 2026
OzempicNo
Adults only, with prior authorization. The criteria require type 2 diabetes, or a liver condition (MASH or MASLD) confirmed by testing.
“Diagnosis of type 2 diabetes mellitus with or without cardiovascular disease and/or chronic kidney disease, as confirmed by chart documentation or claims history”
Criteria for Indiana Medicaid, prepared for the State of Indiana by OptumRx · Effective Jul 1, 2026 · read Nov 6, 2026
MounjaroNo
Age 10 or older, with prior authorization. The criteria require a type 2 diabetes diagnosis.
“MOUNJARO (TIRZEPATIDE) Initial Authorization • Must meet all of the following: o Member is 10 years of age or older o Diagnosis of type 2 diabetes mellitus,”
Criteria for Indiana Medicaid, prepared for the State of Indiana by OptumRx · Effective Jul 1, 2026 · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Jan 1, 2027 · Policy changeUpdated prior authorization criteria for GLP-1 drugs apply to requests from this date. The bulletin does not describe what changed.
“These PA changes will be effective for PA requests submitted on or after Jan.1, 2027.”
Indiana Health Coverage Programs bulletin BT2026184 · Effective Jan 1, 2027 · read Nov 6, 2026
- Nov 6, 2026 · This pageFirst read from Indiana Family and Social Services Administration, with Optum Rx as pharmacy vendor documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Indiana Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Indiana Medicaid as "not covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Indiana Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Indiana Medicaid pay for?
190,013 GLP-1 prescriptions in 2025, 15th of the 50 states and DC, with $203.2 million reimbursed before rebates.
Prescriptions, 2025
190,013
15th of 51
Medicaid paid
$203.2M
15th of 51, before rebates
Per prescription
$1,070
$1,051 nationally
Weight-loss brands
4.6%
25th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Indiana is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 4.6% of Indiana Medicaid's GLP-1 prescriptions in 2025 (8,749). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea.
| Brand | Prescriptions | Share | Medicaid paid |
|---|---|---|---|
| Ozempic | 135,539 | 71% | $145.0 million |
| Trulicity | 29,049 | 15% | $30.7 million |
| Mounjaro | 13,709 | 7.2% | $15.5 million |
| Zepboundapproved for weight management | 5,452 | 2.9% | $5.6 million |
| Wegovyapproved for weight management | 3,297 | 1.7% | $4.3 million |
| Liraglutide (generic) | 1,307 | 0.7% | $491,061 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
On Medicare in Indiana?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Indiana and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Indiana | Not covered | 19 | $41/mo |
| Illinois | Not covered | 19 | $41/moWellmedr |
| Kentucky | Not covered | 18 | $41/moWellmedr |
| Michigan | Covered | 18 | $41/moWellmedr |
| Ohio | Not covered in part | 19 | $41/moWellmedr |






















